Description: Corbus Pharmaceuticals Holdings, Inc., a clinical stage biopharmaceutical company, develops and commercializes novel therapeutics to treat inflammatory-fibrotic diseases. The company primarily develops Resunab, an oral anti-inflammatory drug that has completed Phase I clinical trials for the treatment of cystic fibrosis and diffuse scleroderma. It sells its products through hearing professionals, including audiologists, hearing aid specialists, and ENT doctors worldwide. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
Home Page: www.corbuspharma.com
CRBP Technical Analysis
500 River Ridge Drive
Norwood,
MA
02062
United States
Phone:
617 963 0100
Officers
| Name | Title |
|---|---|
| Dr. Yuval Cohen Ph.D. | CEO & Director |
| Mr. Sean F. Moran CPA, M.B.A., CPA, MBA | Chief Financial Officer |
| Mr. Craig Stuart Millian M.B.A. | Chief Operating Officer |
| Dr. Rachael Brake Ph.D. | Chief Scientific Officer |
| Ted Jenkins | Sr. Director of Investor Relations & Corp. Communications |
| Ms. Lindsey Smith | Head of Corp. Communications & Patient Advocacy |
| Ms. Christina Bertsch | Head of HR |
| Scott Constantine | Sr. Director & Head of Clinical Operations |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.3704 |
| Price-to-Sales TTM: | 163.3187 |
| IPO Date: | 2014-11-11 |
| Fiscal Year End: | December |
| Full Time Employees: | 41 |